Role of HNF1β in the differential diagnosis of yolk sac tumor from other germ cell tumors

Rougemont, Anne‐Laure; Tille, Jean-Christophe

doi:10.1016/j.humpath.2018.04.025

Cited by 21 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, GPC3 immunostaining was also positive in these cases, suggesting small foci of previously undetected YST. The only HNF1β positive choriocarcinoma case exhibited a weak nuclear staining in a background cytoplasmic pattern which was in line with the results of Rougemont and Tille who observed the identical pattern in their cases of choriocarcinomas (4).…”

Section: Discussionsupporting

confidence: 90%

HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors

et al. 2020

View full text Add to dashboard Cite

Hepatocyte Nuclear Factor 1 beta (HNF1) is a transcription factor which plays an important role during early organogenesis, especially of the pancreato-biliary and urogenital tract. Furthermore, HNF1 is an established marker in the differential diagnosis of ovarian cancer and shows a distinct nuclear expression in the clear cell carcinoma subtype. Recently, it has been described in yolk sac tumor, which represents a common component in many non-seminomatous germ cell tumors. Due to its broad histologic diversity, the diagnosis may be challenging and additional tools are very helpful in the workup of germ cell tumors. Immunohistochemistry was used to study HNF1 expression in a tissue microarray (TMA) of 601 testicular germ cell tumors including seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, germ cell neoplasia in situ (GCNIS), and normal tissue. The expression pattern was compared to glypican 3 (GPC3) and -fetoprotein (AFP), two markers currently in use for the detection of yolk sac tumor. HNF1 showed a distinct nuclear staining in comparison to the cytoplasmic pattern of GPC3 and AFP. The sensitivity and specificity of HNF1 were 85.4% and 96.5%, of GPC3 83.3% and 90.7%, of AFP 62.5% and 97.7%. We conclude that HNF1 allows a reliable distinction of yolk sac tumor from other germ cell tumor components. Therefore, we propose HNF1 as a novel and robust marker in the immunohistochemical workup of testicular germ cell tumors.

show abstract

Section: Discussionsupporting

confidence: 90%

HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In particular, the immunohistochemical profile overlaps with that of YST and carcinoma; for example, AE1/AE3 is positive in the current YST, which is not a good marker for differential diagnosis of carcinoma. 25 Although HNF-1β and PAX8 can be patchy positive in YST, 26 both are rather than diffuse positive in clear cell carcinoma. SALL4 is a useful marker for diagnosis when combined with GPC-3 and AFP.…”

Section: Discussionmentioning

confidence: 99%

Pure primary yolk sac tumor of the endometrium tends to occur at a younger age: A case report and literature analysis

2021

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

We present a case of primary yolk sac tumor of the endometrium. This rare tumor occurred in a 43-year-old woman with a pure primary yolk sac tumor. The tumor resembled yolk sac tumor morphology of the ovary. Tumor cells expressed SALL4, AFP, GPC-3, and AE1/AE3 and were focal positive for PAX8. EMA, ER, and PR, among others, were negative. We further analyzed 29 reported cases of this rare tumor in the literature. In total, 17 of 30 patients (57%) had pure endometrial yolk sac tumor, and 13 (43%) had a concomitant somatic neoplasm (endometrial adenocarcinoma was the most common). Although the average age was 52 years (range: 24–87 years), patients with pure yolk sac tumor were younger than those with concomitant somatic tumors, with a mean age of 44.41 years (24–68 years) versus 61.92 years (28–87 years), P = 0.008. Patients with endometrial yolk sac tumor combined with somatic tumor tend to have a slightly higher stage and a poor prognosis.

show abstract

“…AE1/AE3 is positive in both carcinoma and YST, as observed in the current case, and is not a good marker for differential diagnosis [13]. Both HNF-1β and PAX8 can be positive in YST and thus result in an incorrect diagnosis of clear cell carcinoma [14]. However, both marker commonly are patchy positive in YSTs rather than diffuse positive in clear cell carcinoma.…”

Section: Discussionmentioning

confidence: 73%

Primary Yolk Sac Tumor of the Endometrium-----A Case Report and Literature Review

Ge¹,

Bi²

2020

Preprint

View full text Add to dashboard Cite

BackgroundPrimary yolk sac tumor (YST) of the endometrium is extremely rare. We report a case of endometrial YST and review the literature to provide a comprehensive understanding of the diagnosis and management of primary YST of the endometrium.Methods A 43-year-old woman with primary YST of the endometrium is described. We summarize the clinical characteristics, treatments and prognosis of the case reported herein and 29 cases from the literature.ResultsIn a total of 30 primary endometrial YSTs, the average patient age was 52 years (range, 24-87 y). The mean tumor size was 6.94 cm (range 1.3-19.0 cm). Increasing serum levels of AFP were observed in all but one patient. Stage I was more common (12/30, 40%), followed by stages II (5/30, 17%), III (6/30, 20%) and IV (7/30, 23%). Of all 30 patients, 17 (57%) had pure endometrial YST, and 13 (43%) had a concomitant somatic neoplasm representing between <10% and 90% of the tumor, of which endometrial adenocarcinoma was the most common. Patients with pure YST were younger than those with concomitant somatic tumors (ranging from 24-68 years, mean 44.41 years vs. range 28-87 years, mean 61.92 years, P=0.008). Endometrial YSTs with somatic neoplasms had a poorer prognosis than pure YSTs.ConclusionPrimary YST of the endometrium is an extremely rare disease. Surgery combined with adjuvant chemotherapy is the most effective treatment. A late stage and combined somatic components may indicate a poor prognosis.

show abstract

Role of HNF1β in the differential diagnosis of yolk sac tumor from other germ cell tumors

Cited by 21 publications

References 26 publications

HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors

HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors

Pure primary yolk sac tumor of the endometrium tends to occur at a younger age: A case report and literature analysis

Primary Yolk Sac Tumor of the Endometrium-----A Case Report and Literature Review

Contact Info

Product

Resources

About